Literature DB >> 12421462

Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis.

A Hamdan1, P Green, E Mendelson, M R Kramer, S Pitlik, M Weinberger.   

Abstract

During the summer of 2000, a countrywide epidemic of West Nile fever (WNF) occurred in Israel, with 417 confirmed cases and 35 deaths. Immunosuppressed patients had a 31% case-fatality rate, which was significantly higher compared to non-immunosuppressed patients (13%). We describe a 42-year-old male lung-transplant recipient with serologically confirmed West Nile virus (WNV) encephalitis and deteriorating level of consciousness. He was treated with 0.4 g/kg intravenous immunoglobulin preparation from Israeli donors that contained a high titer of anti-WNV antibodies (1 : 1600). The patient showed rapid improvement within 24 h and complete disappearance of signs and symptoms within 48 h. This is the second case of an immunosuppressed patient responding to the same preparation of intravenous immunoglobulins. Larger studies are required in order to establish the therapeutic role of immunoglobulins in patients with WNF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421462     DOI: 10.1034/j.1399-3062.2002.01014.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  35 in total

Review 1.  West Nile virus: a growing concern?

Authors:  L Hannah Gould; Erol Fikrig
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Why the West in West Nile virus infections?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-09       Impact factor: 2.471

Review 3.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

4.  A brief report of West Nile Virus neuroinvasive disease in the summer of 2012 in Hamilton, Ontario.

Authors:  Lei Jiao; Cheryl Main
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

Review 5.  West Nile virus meningoencephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Nat Clin Pract Neurol       Date:  2006-05

Review 6.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  Identification of novel small-molecule inhibitors of West Nile virus infection.

Authors:  Amine O Noueiry; Paul D Olivo; Urszula Slomczynska; Yi Zhou; Ben Buscher; Brian Geiss; Michael Engle; Robert M Roth; Kyung Min Chung; Melanie Samuel; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  West Nile virus surveillance and diagnostics: A Canadian perspective.

Authors:  Michael A Drebot; Robbin Lindsay; Ian K Barker; Peter A Buck; Margaret Fearon; Fiona Hunter; Paul Sockett; Harvey Artsob
Journal:  Can J Infect Dis       Date:  2003-03

Review 9.  Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Authors:  Ponraj Prabakaran; Zhongyu Zhu; Xiaodong Xiao; Arya Biragyn; Antony S Dimitrov; Christopher C Broder; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

10.  West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario.

Authors:  Caitlin Pepperell; Neil Rau; Sigmund Krajden; Ralph Kern; Atul Humar; Barbara Mederski; Andrew Simor; Donald E Low; Allison McGeer; Tony Mazzulli; Jodie Burton; Cheryl Jaigobin; Margaret Fearon; Harvey Artsob; Michael A Drebot; William Halliday; James Brunton
Journal:  CMAJ       Date:  2003-05-27       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.